Browse Studies — Arctuva

Phase 1

A Phase 1, Open-Label, Non-randomized, Single Dose, Safety, Tolerability, and Pharmacokinetic Study of Vorasidenib Administered to Participants With Severe Hepatic Impairment and Matched-Participants With Normal Hepatic Function

The objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of one dose of vorasidenib in participants with severe impaired hepat…

Severe Hepatic ImpairmentNormal Hepatic Function

Estimated

~$500 – $11,250

Actual pay is set by the research site.